English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To assess the correlation between PFS2 and OS among patients with advanced prostate cancer (PC) in a real-world setting for Japan. This was a retrospective analysis using the Japanese MDV database. Patients with nmCRPC (non-metastatic Castration-Resistant PC), mCRPC (metastatic Castration-Resistant PC), and mCNPC (metastatic Castration-Naïve PC) were identified and their medical records were investigated for PFS2 and death. Association between PFS2 and OS was determined using the Pearson’s, Spearman’s, Kendall's Tau, and Fleischers’ correlation coefficients. A total of 386,484 patients with PC were identified from the database, of which, 1,783 patients with nmCRPC, 630 with mCRPC, and 454 with mCNPC met the predefined eligibility criteria. Significant correlation between PFS2 and OS was observed in patients with nmCRPC (Pearson’s  r  = 0.873; 95% CI: 0.849−0.897, Spearman’s  r  = 0.909; 95% CI: 0.893−0.925; Kendall’s Tau  r  = 0.831; 95% CI: 0.812−0.850, Fleischers’  r  = 0.682; 95% CI: 0.601−0.764), mCRPC (Pearson’s  r  = 0.812; 95% CI: 0.758−0.865, Spearman’s  r  = 0.895; 95% CI: 0.868−0.923, Kendall’s Tau  r  = 0.789; 95% CI: 0.755−0.823, Fleischers’  r = 0.439; 95% CI: 0.334−0.544), and mCNPC (Pearson’s  r  = 0.931; 95% CI: 0.899−0.964, Spearman’s  r  = 0.943; 95% CI: 0.922−0.964, Kendall’s Tau  r  = 0.866; 95% CI: 0.836−0.896, Fleischers’  r  = 0.756; 95% CI: 0.624−0.888). The results of this study indicate a significant correlation between PFS2 and OS, which adds additional evidence to the existing literature of using PFS2 as a surrogate endpoint for OS in patients with PC.

current medical research and opinion

Assessing the correlation between second progression-free survival (PFS2) and overall survival (OS) in advanced prostate cancer patients using medical data vision (MDV) claims database in Japan